# Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy

> **NCT02968303** · PHASE2 · UNKNOWN · sponsor: **Radboud University Medical Center** · enrollment: 200 (estimated)

## Conditions studied

- Melanoma, Malignant, of Soft Parts

## Interventions

- **DRUG:** Vemurafenib and Cobimetinib

## Key facts

- **NCT ID:** NCT02968303
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01-27
- **Primary completion:** 2022-10
- **Final completion:** 2023-10
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2020-06-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02968303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02968303, "Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02968303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*